Home
Vidasym is a clinical-stage drug discovery/development company that invents and develops novel drugs for treating serious diseases with significant unmet medical need
The initial focus is on chronic kidney disease complications and osteoporosis
VS-505, a novel phosphate (Pi) binder derived from gum Arabic (GA), has been evaluated in a proof-of-concept clinical trial in hemodialysis patients. VS-505 is highly efficacious with minimal side effects suitable for treating phosphate imbalance in chronic kidney disease. This program is no longer available for licensing.
VS-105, a novel vitamin D receptor agonist (VDRAs), is in clinical studies for the treatment of osteoporosis and hyperparathyroidism secondary to chronic kidney disease. In the completed SAD/MAD studies involving healthy subjects, VS-105 is well tolerated with no drug-related AEs or other issues. The China right of this program has been licensed out. The ex-China right is still available.
Intellectual Property
VDRAs:
Patent exclusivity to 2030: Issued Claims/Notice of Allowance in various countries
Phosphate binders:
Patent exclusivity to 2030+: Issued Claims/Notice of Allowance in various countries